FY2025 · ended Dec 31, 2025 · Revenue $105.97M, +38.9% YoY · Filed Mar 2, 2026
Zymeworks Inc. (ZYME) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $106.0 million and a net loss of $81.1 million. Free cash flow was -$34.5 million. As of Jun 30, 2026 it held $179.4 million in cash and investments and $16.0 million in total debt.
Revenue (TTM)
$37.13M
-69.8% vs year-ago TTM
Net income (TTM)
$-149.99M
-103.6% vs year-ago TTM
Operating cash flow (TTM)
$-119.34M
-208.2% vs year-ago TTM
Free cash flow (TTM)
$-120.54M
-197.9% vs year-ago TTM
EPS (TTM)
$-2.01
-105.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
73.75M
+6.0% vs prior year
Net cash
$163.41M
as of Jun 30, 2026
Operating margin
-419.0%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZYME (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Middletown, DE
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1937653
- Former names
- Zymeworks Delaware Inc. (until Oct 13, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
|---|---|---|---|---|
| Revenue | $106.0M | $76.3M | $76.0M | $412.5M |
| Operating income | -$92.5M | -$137.1M | -$138.1M | $130.5M |
| Net income | -$81.1M | -$122.7M | -$118.7M | $124.3M |
| Diluted EPS | -$1.08 | -$1.62 | -$1.72 | $1.90 |
| Operating cash flow | -$33.0M | -$110.1M | -$118.3M | $144.1M |
| Free cash flow | -$34.5M | -$112.0M | -$120.8M | $136.0M |
| Total assets | $346.5M | $463.1M | $580.9M | $648.7M |
| Total liabilities | $78.0M | $124.3M | $116.1M | $155.8M |
| Stockholders' equity | $268.5M | $338.8M | $464.8M | $493.0M |
| Cash and investments | $41.2M | $66.1M | $456.5M | $493.1M |
| Total debt | $18.3M | $18.5M | $26.8M | $28.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| ARS | Annual report to shareholders | Oct 26, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
Oct 23, 2026 | Oct 22, 2026 |
| 8-K |
Current report
Material agreement, Acquisition or sale of assets, New debt, Regulation FD disclosure
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Aug 25, 2026 | Aug 25, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 6, 2026 | Aug 6, 2026 |
All 337 Zymeworks Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.